1 vote
In an exclusive interview with CNBCTV 18, Kiran Mazumdar Shaw, CMD of Biocon says that Clingene Syngene to undergo transformation in the business model and would wait for a year before listing the IPO. She also expects Pfizer revenues in the next 2436 months.